Case finding of Alpha-1 antitrypsin deficiency: never wasted time!

Bruno Balbi

Alpha-1 Antitrypsin Deficiency (AATD) is considered the most important genetic cause of respiratory disorders, mainly COPD in its emphysematous phenotype [1, 2]. In high risk populations, i.e. those in which a high prevalence of AATD is suspected on the ground of previous data [3], up to 2% of the cases of COPD may, in fact, be due to AATD [4]. This prompted WHO to issue a recommendation that all COPD patients should be tested for AATD at least once in their life in order to ascertain if this genetic condition is underlying their disease [5] Much less strong recommendations are issued about a general population screening [5]. This is actually not recommended if not in high risk populations provided that a genetic counseling is offered to probands [3].

In the last decades many studies were published showing a worldwide distribution of AATD genes in basically the five continents and many regions and countries [6–9]. This type on analysis showed as expected large variations in the frequency of genes carrying the disorder across the different countries. Asia is not an exception to this finding. Allelic frequencies in India differ from those in other countries, e.g. Saudi Arabia. However, these data are often based on rather old studies, sometimes performed on a limited number of individuals.

In this issue of Multidisciplinary Respiratory Medicine, Zhumagaliyeva and Coll. report their data on a case-finding project they performed on a cohort of COPD patients in Kazakhstan [10]. This is the ninth largest country in the world, with an area of 2,724,900 km² “(https://en.wikipedia.org/wiki/Kazakhstan)”.

Capitalizing on a European Respiratory Society Fellowship granted to the first Author of this paper, the study was generated by a collaboration with two of the most important AATD laboratories (the German and the Italian ones), Authors tested 187 patients with COPD and were able to determine the allelic frequencies for Z, S and I (rare) alleles in Kazakhstan. Interestingly, these frequencies were discrepant with those found in a previous, rather old, study performed in Kazakhstan [11]. This may be due to the more sensible and modern methodologies used in this study.

Overall, the results of this study confirm that AATD is present in Kazakhstan. Although the Authors did not find any patient with severe AATD (i.e. homozygous or double heterozygous for alleles carrying AATD), AATD alleles were identified and thus it is possible to estimate that subjects with AATD are in fact present among the population and even more among COPD patients in that country.

What is the lesson we can learn from the paper of Zhumagaliyeva and Coll? I think that fostering new studies on case finding for AATD in COPD is never a wasted effort. Identifying AATD genes in COPD patients may be relevant from many different points of view. Firstly, for the patient as this diagnosis may change entirely the therapeutic approach. Augmentation therapy (AT) with AAT extracted from pooled blood samples from blood donors is potentially available throughout the world and this can change the natural history of the disease. Recent evidences confirmed that AT can slow the loss of lung tissue and consequently of lung function in AATD COPD patients. In doing this AT may add years to the patients’ life [12, 13]. Secondly, and not less important, it is the possibility of genetic testing for the patient’s family members, the so called non-index cases as opposed to the patient with diagnosed AATD, the index case. Testing may unveil new cases of AATD, usually diagnosed in less severe stages of the disease, leaving thus more space for secondary prevention and treatment. Last but not least, case-finding of AATD in COPD patients is a “must” in the third millennium medicine. Unvealing the genetic background should not be an episodic activity in modern medicine, especially when after a genetic diagnosis a disease-modifying treatment is potentially available.
Acknowledgements
Not applicable

Funding
Not applicable

Availability of data and materials
Not applicable

Authors’ contributions
Not applicable

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The author declares that he has no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 23 October 2017 Accepted: 28 November 2017
Published online: 20 January 2018

References
1. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 antitrypsin deficiency. Am J Med. 1988;84:13–31.
2. Stolk J, Seersholm N, Kalshkeker N. Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis. 2006;1:151–60.
3. Corda L, Medicina D, La Piana GE, Bertella E, Moretti G, Bianchi L, et al. Population genetic screening for alpha1-antitrypsin deficiency in a high-prevalence area. Respiration. 2011;82(5):418–25.
4. Vogelmeier CF, Cirrino GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. A Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49:1700214.
5. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900.
6. De Serres FJ, Blanco I, Fernandez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening. COPD. 2006;3:133–9.
7. de Serres FJ, Blanco I, Fernandez-Bustillo E. Health implications of alpha1-antitrypsin deficiency in sub-Saharan African countries and their emigrants in Europe and the new world. Genet Med. 2005;7:175–84.
8. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64:382–97.
9. de Serres FJ, Blanco I, Fernandez-Bustillo E. Estimated numbers and prevalence of PiS and PiZ deficiency alleles of alpha-1antitrypsin deficiency in Asia. Eur Respir J. 2006;28:1091–9.
10. Zhumagaliyeva A, Ottaviani S, Greulich T, Gontini M, Vogelmeier C, Karazhanova L, et al. Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD. Multidiscip Respir Med 2017;12:xx. DOI https://doi.org/10.1186/s40248-017-0104-5.
11. Petrišev VN, Lebedeva IA, Shneider IV. Genetic polymorphism of the alpha-1-antitrypsin system in the native population of the Kazakh SSR. Genetika. 1987;23:257–64.
12. Chapman KP, Burdon JG, Piktulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–8.
13. Balbi B, Ferrarotti I, Miravitlles M. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough. Eur Respir J. 2016;47(1):35–8.